- Home
- RNTX vs CALC Comparison
RNTX vs CALC Comparison
Compare RNTX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- CALC
- Stock Information
- Founded
- RNTX 2001
- CALC 2011
- Country
- RNTX United States
- CALC United States
- Employees
- RNTX N/A
- CALC N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- RNTX Health Care
- CALC Health Care
- Exchange
- RNTX Nasdaq
- CALC Nasdaq
- Market Cap
- RNTX 44.2M
- CALC 20.9M
- IPO Year
- RNTX N/A
- CALC N/A
- Fundamental
- Price
- RNTX $1.72
- CALC $2.07
- Analyst Decision
- RNTX
- CALC Strong Buy
- Analyst Count
- RNTX 0
- CALC 3
- Target Price
- RNTX N/A
- CALC $16.33
- AVG Volume (30 Days)
- RNTX 27.4K
- CALC 28.2K
- Earning Date
- RNTX 05-19-2025
- CALC 05-20-2025
- Dividend Yield
- RNTX N/A
- CALC N/A
- EPS Growth
- RNTX N/A
- CALC N/A
- EPS
- RNTX N/A
- CALC N/A
- Revenue
- RNTX N/A
- CALC N/A
- Revenue This Year
- RNTX N/A
- CALC N/A
- Revenue Next Year
- RNTX N/A
- CALC N/A
- P/E Ratio
- RNTX N/A
- CALC N/A
- Revenue Growth
- RNTX N/A
- CALC N/A
- 52 Week Low
- RNTX $1.35
- CALC $1.43
- 52 Week High
- RNTX $4.40
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- CALC 63.05
- Support Level
- RNTX N/A
- CALC $1.52
- Resistance Level
- RNTX N/A
- CALC $2.15
- Average True Range (ATR)
- RNTX 0.00
- CALC 0.13
- MACD
- RNTX 0.00
- CALC 0.08
- Stochastic Oscillator
- RNTX 0.00
- CALC 73.61
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.